MedTrace Logo

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

NCT01789736 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2014-03-17

No results posted yet for this study

Summary

In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.

Conditions

Interventions

DRUG

PG286 Ophthalmic Solution 0.5%

PG286 Ophthalmic Solution

DRUG

AR-12286 Ophthalmic Solution 0.5%

AR-12286 Ophthalmic Solution 0.5%

DRUG

Travoprost Ophthalmic Solution 0.004%

Travoprost Ophthalmic Solution 0.004%

Sponsors & Collaborators

  • Aerie Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01789736 on ClinicalTrials.gov